{{Rsnum
|rsid=11591741
|Gene=CHUK
|Chromosome=10
|position=101976501
|Orientation=plus
|GMAF=0.2277
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 13.8 | 56.9 | 29.2
| HCB | 0.0 | 22.2 | 77.8
| JPT | 0.0 | 4.4 | 95.6
| YRI | 0.0 | 6.3 | 93.7
| ASW | 0.0 | 0.0 | 0.0
| CHB | 0.0 | 22.2 | 77.8
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}

{{omim
|desc=ALANINE AMINOTRANSFERASE, PLASMA LEVEL OF, QUANTITATIVE TRAIT LOCUS
|id=612363
|rsnum=11591741
}}

{{PMID|18940312|OA=1
}} Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes.

{{PMID|20448286}} Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.

{{PMID Auto
|PMID=23477746
|Title=The ERLIN1-CHUK-CWF19L1 gene cluster influences liver fat deposition and hepatic inflammation in the NHLBI Family Heart Study.
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}